Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Risk of Atrophic Acne Scar Formation During Treatment of Acne Vulgaris Subjects With Trifarotene 50 μg/g Cream Versus Vehicle Cream Over 24 Weeks

NCT04856904 is registered in ClinicalTrials.gov with Galderma R&D as lead sponsor.

NCT NCT04856904
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04856904 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Risk of Atrophic Acne Scar Formation During Treatment of Acne Vulgaris Subjects With Trifarotene 50 μg/g Cream Versus Vehicle Cream Over 24 Weeks
Lead sponsor
Galderma R&D
Phase
Phase 4
Overall status
Completed
Start date
May 28, 2021
Completion date
June 30, 2023
Enrollment
121 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

acne vulgaris